Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program

Journal of Clinical Immunology

Volumn 36, Issue 5, 2016, Pages 502-510

  Perraudin, Clemence ^a,b   Bourdin, Aline ^a,b   Spertini, Francois ^c   Berger, Jérôme ^a,b   Bugnon, Olivier ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Immunoglobulin; interprofessional; intravenous; management program; subcutaneous

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFUSION PUMP; MEDICATION THERAPY MANAGEMENT; OUTPATIENT DEPARTMENT; PHARMACIST; PRIORITY JOURNAL; TRAFFIC AND TRANSPORT; ADULT; COST; COST BENEFIT ANALYSIS; ECONOMICS; HOME CARE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; IMMUNOTHERAPY; NURSE; PATIENT CARE; PHYSICIAN; SUBCUTANEOUS DRUG ADMINISTRATION; SWITZERLAND;

ADULT; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HOME CARE SERVICES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INFUSIONS, SUBCUTANEOUS; MEDICATION THERAPY MANAGEMENT; NURSES; PATIENT CARE TEAM; PHYSICIANS; SWITZERLAND;

EID: 84965047549     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0288-z     Document Type: Article

References (32)

1. APIIEG. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency: Asia Pacific Immunoglobulins in Immunology Expert Group 2009.
2. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1–11. doi:10.1111/j.1365-2249.2005.02834.x.
3. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61–70. doi:10.1007/s12026-011-8241-y.
4. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8.
5. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153–64. doi:10.1007/s10875-012-9740-x.
6. European Society for Immunodeficiencies (ESID). http://esid.org/. 2015.
7. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Adv Ther. 2011;28(7):521–33. doi:10.1007/s12325-011-0036-y.
8. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.
9. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–42. doi:10.1016/j.jaci.2004.06.053.
10. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65–72. doi:10.1007/s10875-006-8905-x.
11. Shapiro RS. Why I, use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33 Suppl 2:S95–8. doi:10.1007/s10875-012-9853-2.
12. Simoens S. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. Expert Rev Pharmacoecon Outcomes Res. 2009;9(4):375–86. doi:10.1586/erp.09.37.
13. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345(8946):365–9.
14. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6(1):24–9. doi:10.1007/s10198-004-0250-5.
15. Beaute J, Levy P, Millet V, Debre M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240–5. doi:10.1111/j.1365-2249.2009.04079.x.
16. Haddad L, Perrinet M, Parent D, Leroy-Cotteau A, Toguyeni E, Condette-Wojtasik G, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. Rev Med Interne. 2006;27(12):924–6. doi:10.1016/j.revmed.2006.08.005.
17. Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014;35(7):1023–34. doi:10.1007/s10072-014-1632-9.
18. Cocito D, Serra G, Paolasso I, Barila DA, Lopiano L, Cattel L. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. J Peripher Nerv Syst. 2012;17(4):426–8. doi:10.1111/j.1529-8027.2012.00444.x.
19. Liu Z, Albon E, GHyde C, WMHTA C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. University of Birmingham: Department of Public Health and Epidemiology2005.
20. Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am. 2008;28(4):861–74. doi:10.1016/j.iac.2008.06.008.
21. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60. doi:10.1111/j.1365-3148.2012.01201.x.
22. Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28(4):370–8. doi:10.1007/s10875-008-9180-9.
23. Gardulf A, Moller G, Jonsson E. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care. 1995;11(2):345–53.
24. Bourdin A, Berger J, Bugnon O. Immunoglobulin self-infusion: an interprofessional drug therapy management program. 42nd European Symposium on Clinical Pharmacy symposium on Clinical Pharmacy: Implementation of Pharmacy Practice; 16-18 October 2013; Prague, Czech Republic: International Journal of Clinical Pharmacy; 2013. p. 1281-2.
25. Bourdin A, Berger J, Fruh A, Spertini F, Bugnon O. Subcutaneous immunoglobulin and support program: what level of interest of patients? Rev Med Suisse. 2015;11(469):831–5.
26. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131(2):585-7 e1-3. doi:10.1016/j.jaci.2012.08.022.
27. Drummond MF. Sculpher MJ. Torrance GW: O’Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 2005.
28. Henderson K. Training and support to enable home immunoglobulin therapy. Nurs Times. 2003;99(45):28–31.
29. Gardulf A, Bjorvell H, Andersen V, Bjorkander J, Ericson D, Froland SS, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients’ experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995;21(5):917–27.
30. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21(2):105–16.
31. Bourdin A, Berger J, Perraudin C, Bugnon O. Therapy management program for immunoglobulin self-infusion: patients’ reported outcomes. 43rd European Symposium on Clinical Pharmacy: Patient Safety - Bridging the Gaps; 22–24 October 2014; Copenaghen, Denmark: International Journal of Clinical Pharmacy; 2014. p. p 179-287.
32. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities—ongoing questions. J Clin Immunol. 2013;33 Suppl 2:S99–103. doi:10.1007/s10875-012-9851-4.